126,08 €
0,58 %heute
L&S, 28. März, 16:53 Uhr
ISIN
GB0009895292
Symbol
AZN
Sektor
Industrie

AstraZeneca Aktie News

Positiv
InvestorPlace
etwa 3 Stunden alt
Blue-chip stocks are associated with a low-beta, stable returns, and passive dividend income for investors. However, not all blue-chip stocks are comparable when it comes to returns over a time-frame.
Positiv
The Motley Fool
etwa 3 Stunden alt
Alexandria Real Estate Equities is a major owner of specialized lab and office space. American Tower is a global leader in telecommunications infrastructure.
Positiv
Seeking Alpha
3 Tage alt
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to...
Positiv
InvestorPlace
8 Tage alt
In my view, a sure-shot way of minting money from the markets is buying and holding with patience. Of course, the idea needs to be well-researched as a first step.
Positiv
Schaeffers Research
9 Tage alt
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) stock is skyrocketing today, after news that AstraZeneca (AZN) is acquiring the Canadian biotech company for $2.4 billion, or $21 per share.
Positiv
Investors Business Daily
9 Tage alt
AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.
Positiv
Proactive Investors
9 Tage alt
AstraZeneca PLC (LSE:AZN) is acquiring Canada's Fusion Pharmaceuticals for $2.4 billion, in a bid to effectively 'keep up with Joneses' as it seeks to challenge Novartis, which is blazing a trail in targeted cancer treatment. Fusion specialises in the development of radioconjugates, which focuses on delivering radioactive isotopes directly to cancer cells through precise targeting mechanisms.
Neutral
Business Wire
9 Tage alt
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens li...
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen